{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:01:40Z","timestamp":1792612900978,"version":"4.5.0"},"reference-count":162,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a membrane receptor that plays a key role in development. It is highly expressed during the embryonic stage and relatively low in some normal adult tissues. Malignancies such as leukemia, lymphoma, and some solid tumors overexpress ROR1, making it a promising target for cancer treatment. Moreover, immunotherapy with autologous T-cells engineered to express a ROR1-specific chimeric antigen receptor (ROR1 CAR-T cells) has emerged as a personalized therapeutic option for patients with tumor recurrence after conventional treatments. However, tumor cell heterogeneity and tumor microenvironment (TME) hinder successful clinical outcomes. This review briefly describes the biological functions of ROR1 and its relevance as a tumor therapeutic target, as well as the architecture, activity, evaluation, and safety of some ROR1 CAR-T cells used in basic research and clinical trials. Finally, the feasibility of applying the ROR1 CAR-T cell strategy in combination with therapies targeting other tumor antigens or with inhibitors that prevent tumor antigenic escape is also discussed.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/<\/jats:ext-link>\n                      , identifier NCT02706392\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2023.1121020","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:20:05Z","timestamp":1676593205000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Anti-ROR1 CAR-T cells: Architecture and performance"],"prefix":"10.3389","volume":"10","author":[{"given":"Daniel Andr\u00e9s","family":"Osorio-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo Armando","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Ram\u00edrez-Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"key":"B1","year":"2022","journal-title":"Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review.","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA."},{"key":"B4","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.trecan.2020.04.010","article-title":"Advanced prostate cancer: treatment advances and future directions.","volume":"6","author":"Swami","year":"2020","journal-title":"Trends Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1126\/science.276.5316.1268","article-title":"Gene expression profiles in normal and cancer cells.","volume":"276","author":"Zhang","year":"1997","journal-title":"Science."},{"key":"B6","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/carcin\/23.6.967","article-title":"Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells.","volume":"23","author":"Karan","year":"2002","journal-title":"Carcinogenesis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"17266","DOI":"10.1073\/pnas.1419599111","article-title":"Ovarian cancer stem cells express ROR1, which can be targeted for anti\u2013cancer-stem-cell therapy.","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ccr.2013.09.004","article-title":"EGFR phosphorylates tumor-derived EGFRvIII driving STAT3\/5 and progression in glioblastoma.","volume":"24","author":"Fan","year":"2013","journal-title":"Cancer Cell."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031127","article-title":"ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth.","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/j.ajpath.2012.08.024","article-title":"The onco-embryonic antigen ROR1 is expressed by a variety of human cancers.","volume":"181","author":"Zhang","year":"2012","journal-title":"Am J Pathol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget."},{"key":"B12","article-title":"Stable silencing of ROR1 regulates cell cycle, apoptosis, and autophagy in a lung adenocarcinoma cell line.","volume":"13","author":"Zhou","year":"2020","journal-title":"Int J Clin Exp Pathol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2741\/1642","article-title":"The role of the tumor microenvironment in hematological malignancies and implication for therapy.","volume":"10","author":"Zhou","year":"2005","journal-title":"Front Biosci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.blre.2005.08.003","article-title":"Tumor microenvironment and drug resistance in hematologic malignancies.","volume":"20","author":"Li","year":"2006","journal-title":"Blood Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ctrv.2018.02.004","article-title":"Targeting the microenvironment in solid tumors.","volume":"65","author":"Belli","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/CCO.0000000000000232","article-title":"Smart CARs engineered for cancer immunotherapy.","volume":"27","author":"Priceman","year":"2015","journal-title":"Curr Opin Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.it.2020.06.010","article-title":"Organoid models of tumor immunology.","volume":"41","author":"Yuki","year":"2020","journal-title":"Trends Immunol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603640","article-title":"3D Tumor models and their use for the testing of immunotherapies.","volume":"11","author":"Boucherit","year":"2020","journal-title":"Front Immunol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01104","article-title":"Perspectives on chimeric antigen receptor T-cell immunotherapy for solid tumors.","volume":"9","author":"Kosti","year":"2018","journal-title":"Front Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1073\/pnas.1812266115","article-title":"Blocking IL-1\u03b2 reverses the immunosuppression in mouse breast cancer and synergizes with anti\u2013PD-1 for tumor abrogation.","volume":"116","author":"Kaplanov","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s40265-021-01539-5","article-title":"Dostarlimab: first approval.","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer.","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition.","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000676","article-title":"Inhibition of TGF-beta-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer.","volume":"8","author":"Stuber","year":"2020","journal-title":"J Immunother Cancer."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment.","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1083\/jcb.201102147","article-title":"The extracellular matrix: a dynamic niche in cancer progression.","volume":"196","author":"Lu","year":"2012","journal-title":"J Cell Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004479","article-title":"Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells.","volume":"10","author":"Mart\u00edn-Otal","year":"2022","journal-title":"J Immunother Cancer."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma.","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/0008-5472.CAN-11-0422","article-title":"In Vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).","volume":"71","author":"Song","year":"2011","journal-title":"Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1470-2045(19)30088-9","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.","volume":"20","author":"Shitara","year":"2019","journal-title":"Lancet Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab govitecan: first approval.","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood."},{"key":"B35","first-page":"25","article-title":"Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR\/HER-2 heterodimerization and activation.","volume":"34","author":"Patel","year":"2009","journal-title":"Int J Oncol."},{"key":"B36","first-page":"3355","article-title":"Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface.","volume":"27","author":"Patel","year":"2007","journal-title":"Anticancer Res."},{"key":"B37","first-page":"165","article-title":"Monoclonal antibody against ROR1 induces apoptosis in human bladder carcinoma cells.","volume":"12","author":"Bayat","year":"2020","journal-title":"Avicenna J Med Biotechnol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline.","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov."},{"key":"B39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/BTT.S202746","article-title":"Blinatumomab for the treatment of adult B-cell acute lymphoblastic leukemia: toward a new era of targeted immunotherapy.","volume":"14","author":"Franquiz","year":"2020","journal-title":"Biol Targets Ther."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1326437","article-title":"An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors.","volume":"6","author":"Gohil","year":"2017","journal-title":"Oncoimmunology."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy.","volume":"13","author":"Hemminki","year":"2020","journal-title":"J Hematol OncolJ Hematol Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s40259-022-00553-7","article-title":"Teserpaturev\/G47\u0394: first approval.","volume":"36","author":"Frampton","year":"2022","journal-title":"BioDrugs."},{"key":"B43","doi-asserted-by":"publisher","first-page":"12369","DOI":"10.1002\/jcp.28058","article-title":"MicroRNA replacement therapy in cancer.","volume":"234","author":"Mollaei","year":"2019","journal-title":"J Cell Physiol."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153818","article-title":"miRacle of microRNA-driven cancer nanotherapeutics.","volume":"14","author":"Kara","year":"2022","journal-title":"Cancers."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112680","article-title":"MicroRNA therapeutics in cancer: current advances and challenges.","volume":"13","author":"Reda El Sayed","year":"2021","journal-title":"Cancers."},{"key":"B46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jare.2020.08.012","article-title":"Therapeutic advances of miRNAs: a preclinical and clinical update.","volume":"28","author":"Chakraborty","year":"2021","journal-title":"J Adv Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma.","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10555-021-09968-0","article-title":"Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.","volume":"40","author":"Nelson","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/14712598.2022.2072206","article-title":"Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms.","volume":"22","author":"Nowroozi","year":"2022","journal-title":"Expert Opin Biol Ther."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126345","article-title":"ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models.","volume":"4","author":"Wallstabe","year":"2019","journal-title":"JCI Insight."},{"key":"B51","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/2326-6066.CIR-14-0163","article-title":"Safety of targeting ROR1 in primates with chimeric antigen receptor\u2013modified T cells.","volume":"3","author":"Berger","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205108","article-title":"Advances and hurdles in CAR T cell immune therapy for solid tumors.","volume":"14","author":"Boccalatte","year":"2022","journal-title":"Cancers."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-Specific chimeric antigen receptor T cells.","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia.","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211019622","article-title":"The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma.","volume":"12","author":"Oriol","year":"2021","journal-title":"Ther Adv Hematol."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up.","author":"Martin","year":"2022","journal-title":"J Clin Oncol."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.878209","article-title":"CAR-T cell performance: how to improve their persistence?.","volume":"13","author":"L\u00f3pez-Cantillo","year":"2022","journal-title":"Front Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: current challenges and opportunities.","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol Ther Oncolytics."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities.","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126342","article-title":"All good things must end: termination of receptor tyrosine kinase signal.","volume":"22","author":"Margiotta","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.tcb.2008.08.006","article-title":"Ror receptor tyrosine kinases: orphans no more.","volume":"18","author":"Green","year":"2008","journal-title":"Trends Cell Biol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1242\/jcs.01622","article-title":"Neurite extension in central neurons: a novel role for the receptor tyrosine kinases Ror1 and Ror2.","volume":"118","author":"Paganoni","year":"2005","journal-title":"J Cell Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0925-4773(01)00383-5","article-title":"Expression of the receptor tyrosine kinase genes, Ror1 and Ror2, during mouse development.","volume":"105","author":"Matsuda","year":"2001","journal-title":"Mech Dev."},{"key":"B66","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1046\/j.1365-2443.1999.00234.x","article-title":"Spatio-temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during mouse development: implications in development and function of the nervous system.","volume":"4","author":"Oishi","year":"1999","journal-title":"Genes Cells."},{"key":"B67","doi-asserted-by":"publisher","first-page":"26181","DOI":"10.1016\/S0021-9258(18)35733-8","article-title":"A novel family of cell surface receptors with tyrosine kinase-like domain.","volume":"267","author":"Masiakowski","year":"1992","journal-title":"J Biol Chem."},{"key":"B68","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00018-002-8407-9","article-title":"The Ror receptor tyrosine kinase family.","volume":"59","author":"Forrester","year":"2002","journal-title":"Cell Mol Life Sci."},{"key":"B69","year":"2022","journal-title":"UniProt."},{"key":"B70","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.biopha.2017.01.070","article-title":"Receptor tyrosine kinase-like orphan receptor 1 (ROR-1): an emerging target for diagnosis and therapy of chronic lymphocytic leukemia.","volume":"88","author":"Aghebati-Maleki","year":"2017","journal-title":"Biomed Pharmacother."},{"key":"B71","first-page":"1555","article-title":"Human neural tissues express a truncated Ror1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains.","volume":"13","author":"Reddy","year":"1996","journal-title":"Oncogene."},{"key":"B72","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/dvdy.151","article-title":"Role of noncanonical Wnt ligands and Ror-family receptor tyrosine kinases in the development, regeneration, and diseases of the musculoskeletal system.","volume":"250","author":"Kamizaki","year":"2021","journal-title":"Dev Dyn."},{"key":"B73","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1748-1716.2011.02306.x","article-title":"Post-translational modifications regulate signalling by Ror1.","volume":"203","author":"Kaucka","year":"2011","journal-title":"Acta Physiol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","article-title":"Analysis of ROR1 protein expression in human cancer and normal tissues.","volume":"23","author":"Balakrishnan","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B75","year":"2022","journal-title":"Tissue expression of ROR1 - summary."},{"key":"B76","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/73488","article-title":"Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage and growth plate development.","volume":"24","author":"DeChiara","year":"2000","journal-title":"Nat Genet."},{"key":"B77","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/73495","article-title":"Dominant mutations in ROR2, encoding an orphan receptor tyrosine kinase, cause brachydactyly type B.","volume":"24","author":"Oldridge","year":"2000","journal-title":"Nat Genet."},{"key":"B78","doi-asserted-by":"publisher","first-page":"8329","DOI":"10.1128\/MCB.21.24.8329-8335.2001","article-title":"Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2 -deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases.","volume":"21","author":"Nomi","year":"2001","journal-title":"Mol Cell Biol."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00034","article-title":"ROR1 and ROR2 in human malignancies: potentials for targeted therapy.","volume":"2","author":"Rebagay","year":"2012","journal-title":"Front Oncol."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/srep36447","article-title":"ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma.","volume":"6","author":"Zheng","year":"2016","journal-title":"Sci Rep."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/srep05811","article-title":"ROR1 expression correlated with poor clinical outcome in human ovarian cancer.","volume":"4","author":"Zhang","year":"2015","journal-title":"Sci Rep."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-019-0131-9","article-title":"Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis.","volume":"5","author":"Hasan","year":"2019","journal-title":"Npj Breast Cancer."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1073\/pnas.1816262116","article-title":"Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040837","article-title":"The anti-ROR1 monoclonal antibody zilovertamab inhibits the proliferation of ovarian and endometrial cancer cells.","volume":"14","author":"Liu","year":"2022","journal-title":"Pharmaceutics."},{"key":"B85","doi-asserted-by":"publisher","first-page":"40310","DOI":"10.18632\/oncotarget.5643","article-title":"Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.","volume":"6","author":"Henry","year":"2015","journal-title":"Oncotarget."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9394615","article-title":"Ovarian cancer stem cells with high ROR1 expression serve as a new prophylactic vaccine for ovarian cancer.","volume":"2019","author":"Wu","year":"2019","journal-title":"J Immunol Res."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127092","article-title":"Silencing of receptor tyrosine kinase ROR1 inhibits tumor-cell proliferation via PI3K\/AKT\/mTOR signaling pathway in lung adenocarcinoma.","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/cells8030210","article-title":"ROR1 expression and its functional significance in hepatocellular carcinoma cells.","volume":"8","author":"Cetin","year":"2019","journal-title":"Cells."},{"key":"B89","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.anndiagpath.2015.06.010","article-title":"Expression of ROR1, pAkt, and pCREB in gastric adenocarcinoma.","volume":"19","author":"Chang","year":"2015","journal-title":"Ann Diagn Pathol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3892\/or.2020.7681","article-title":"Retinoic acid induces differentiation in neuroblastoma via ROR1 by modulating retinoic acid response elements.","volume":"44","author":"Illendula","year":"2020","journal-title":"Oncol Rep."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/mc.22426","article-title":"ROR1 contributes to melanoma cell growth and migration by regulating N-cadherin expression via the PI3K\/Akt pathway: ROR1 increases melanoma cell growth and migration.","volume":"55","author":"Fern\u00e1ndez","year":"2016","journal-title":"Mol Carcinog."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217789","article-title":"Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K\/AKT\/GSK3\u00df activity.","volume":"14","author":"Fultang","year":"2019","journal-title":"PLoS One."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8060170","article-title":"ROR1 is expressed in diffuse large B-cell lymphoma (DLBCL) and a small molecule inhibitor of ROR1 (KAN0441571C) induced apoptosis of lymphoma cells.","volume":"8","author":"Ghaderi","year":"2020","journal-title":"Biomedicines."},{"key":"B94","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1158\/0008-5472.CAN-12-3832","article-title":"Targeting ROR1 inhibits epithelial\u2013mesenchymal transition and metastasis.","volume":"73","author":"Cui","year":"2013","journal-title":"Cancer Res."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3390\/cells8101118","article-title":"The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges.","volume":"8","author":"Loh","year":"2019","journal-title":"Cells."},{"key":"B96","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.3892\/mmr.2018.9500","article-title":"ROR1 is highly expressed in circulating tumor cells and promotes invasion of pancreatic cancer.","volume":"18","author":"Xu","year":"2018","journal-title":"Mol Med Rep."},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052655","article-title":"Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies.","volume":"7","author":"Dave","year":"2012","journal-title":"PLoS One."},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078339","article-title":"The Tyrosine kinase receptor ror1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.","volume":"8","author":"Hojjat-Farsangi","year":"2013","journal-title":"PLoS One."},{"key":"B99","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1182\/bloodadvances.2020003276","article-title":"The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia.","volume":"5","author":"Hu","year":"2021","journal-title":"Blood Adv."},{"key":"B100","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1172\/JCI83535","article-title":"Wnt5a induces ROR1\/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.","volume":"126","author":"Yu","year":"2015","journal-title":"J Clin Invest."},{"key":"B101","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer.","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat Biomed Eng."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00173","article-title":"Paired expression analysis of tumor cell surface antigens.","volume":"7","author":"Orentas","year":"2017","journal-title":"Front Oncol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor\u2013associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1016\/j.jmb.2017.08.003","article-title":"Mining na\u00efve rabbit antibody repertoires by phage display for monoclonal antibodies of therapeutic utility.","volume":"429","author":"Peng","year":"2017","journal-title":"J Mol Biol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","article-title":"Enhanced safety and efficacy of protease-regulated CAR-T cell receptors.","volume":"185","author":"Labanieh","year":"2022","journal-title":"Cell."},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153618","article-title":"Developing ROR1 targeting CAR-T cells against solid tumors in preclinical studies.","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128151","article-title":"Sleeping beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinase-like orphan receptor-1 (ROR1) into diverse memory T-cell populations.","volume":"10","author":"Deniger","year":"2015","journal-title":"PLoS One"},{"key":"B108","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting.","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell."},{"key":"B109","doi-asserted-by":"publisher","first-page":"349","DOI":"10.4161\/mabs.19870","article-title":"Targeting malignant B cells with an immunotoxin against ROR1.","volume":"4","author":"Baskar","year":"2012","journal-title":"MAbs."},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021018","article-title":"Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.","volume":"6","author":"Yang","year":"2011","journal-title":"PLoS One."},{"key":"B111","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy.","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics."},{"key":"B113","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","article-title":"Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity.","volume":"75","author":"Caruso","year":"2015","journal-title":"Cancer Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits.","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell."},{"key":"B115","author":"Nathwani","year":"2019","journal-title":"Ror1 car T-cells."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.5772\/52534","article-title":"Lentiviral gene therapy vectors: challenges and future directions.","author":"Toma\u00ecs","year":"2013","journal-title":"Gene therapy - tools and potential applications."},{"key":"B117","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/imr.12137","article-title":"A new approach to gene therapy using sleeping beauty to genetically modify clinical-grade T cells to target CD19.","volume":"257","author":"Singh","year":"2014","journal-title":"Immunol Rev."},{"key":"B118","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1158\/0008-5472.CAN-07-5600","article-title":"Redirecting specificity of T-cell populations For CD19 using the sleeping beauty system.","volume":"68","author":"Singh","year":"2008","journal-title":"Cancer Res."},{"key":"B119","doi-asserted-by":"publisher","first-page":"p. 69","DOI":"10.1007\/978-1-0716-0146-4_5","article-title":"Optimized production of lentiviral vectors for CAR-T cell.","author":"Mo\u00e7o","year":"2020","journal-title":"Chimeric antigen receptor T cells. Methods in molecular biology."},{"key":"B120","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/10408363.2019.1633512","article-title":"Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects.","volume":"56","author":"Poorebrahim","year":"2019","journal-title":"Crit Rev Clin Lab Sci."},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1032397","article-title":"Sleeping beauty generated CD19 CAR T-cell therapy for advanced B-Cell hematological malignancies.","volume":"13","author":"Singh","year":"2022","journal-title":"Front Immunol."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133152","article-title":"IGF1R- and ROR1-specific CAR T cells as a potential therapy for high risk sarcomas.","volume":"10","author":"Huang","year":"2015","journal-title":"PLoS One."},{"key":"B123","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2217\/pme-2017-0047","article-title":"New synthetic 3D culture systems to unlock the future of organoids in research and therapy.","volume":"14","author":"Sanctuary","year":"2017","journal-title":"Pers Med."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176225","article-title":"Spheroids as a type of three-dimensional cell cultures\u2014examples of methods of preparation and the most important application.","volume":"21","author":"Bia\u0142kowska","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B125","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s11899-016-0336-z","article-title":"Chimeric antigen receptor T cells for B cell neoplasms: choose the right CAR for you.","volume":"11","author":"Ruella","year":"2016","journal-title":"Curr Hematol Malig Rep."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia.","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med."},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018100928","article-title":"3D model for CAR -mediated cytotoxicity using patient-derived colorectal cancer organoids.","volume":"38","author":"Schnalzger","year":"2019","journal-title":"EMBO J."},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28313","article-title":"VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma.","volume":"67","author":"Englisch","year":"2020","journal-title":"Pediatr Blood Cancer."},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201900001","article-title":"Evaluating CAR-T Cell Therapy in a Hypoxic 3D Tumor Model.","volume":"8","author":"Ando","year":"2019","journal-title":"Adv Healthc Mater."},{"key":"B130","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade.","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell."},{"key":"B131","year":"2023","journal-title":"Search of: ROR 1 CAR T - list results."},{"key":"B132","author":"Maloney","year":"2022","journal-title":"Phase I study of adoptive immunotherapy for advanced ROR1+ malignancies with defined subsets of autologous T cells engineered to express a ROR1-specific chimeric antigen receptor. [Clinical trial registration]."},{"key":"B133","doi-asserted-by":"publisher","first-page":"P2","DOI":"10.1158\/1538-7445.SABCS18-P2-09-13","article-title":"Abstract P2-09-13: a phase I study of adoptive immunotherapy for ROR1+ advanced triple negative breast cancer (TNBC) with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR).","volume":"79","author":"Specht","year":"2019","journal-title":"Cancer Res."},{"key":"B134","year":"2022","journal-title":"A phase 1 study to assess the safety and efficacy of LYL797, ROR1-targeting CAR T cells, in adults with relapsed and\/or refractory solid-tumor malignancies. [Clinical trial registration]."},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-2754","article-title":"Abstract 2754: LYL797, a ROR1 CAR T-cell therapy with genetic and epigenetic reprogramming for solid tumors.","volume":"82","author":"Park","year":"2022","journal-title":"Cancer Res."},{"key":"B136","year":"2017","journal-title":"A study to infuse ROR1-specific autologous T cells for patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL). [Clinical trial registration]."},{"key":"B137","author":"Lin","year":"2022","journal-title":"A study of RD14-01 in patients with advanced solid tumors. [Clinical trial registration]."},{"key":"B138","year":"2022","journal-title":"Phase 1\/2 multi-center study to evaluate the safety and efficacy of ONCT-808 in adult subjects with relapsed or refractory aggressive B-cell malignancies. [Clinical trial registration]."},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3390\/life12040561","article-title":"CAR-T cells for the treatment of lung cancer.","volume":"12","author":"Chocarro","year":"2022","journal-title":"Life."},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med."},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092523","article-title":"Bispecific chimeric antigen receptor T cell therapy for B cell malignancies and multiple myeloma.","volume":"12","author":"Cronk","year":"2020","journal-title":"Cancers."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy.","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"B143","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape.","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature."},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01209-9","article-title":"Born to survive: how cancer cells resist CAR T cell therapy.","volume":"14","author":"Lemoine","year":"2021","journal-title":"J Hematol OncolJ Hematol Oncol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia.","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv."},{"key":"B146","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy.","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol."},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.969020","article-title":"Combating challenges in CAR-T cells with engineering immunology.","volume":"10","author":"Wang","year":"2022","journal-title":"Front Cell Dev Biol."},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.969660","article-title":"Decitabine-primed tandem CD19\/CD22 CAR-T therapy in relapsed\/refractory diffuse large B-cell lymphoma patients.","volume":"13","author":"Qu","year":"2022","journal-title":"Front Immunol."},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00192-6","article-title":"Characterization of novel dual tandem CD19\/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma.","volume":"8","author":"Kang","year":"2020","journal-title":"Biomark Res."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med."},{"key":"B151","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics."},{"key":"B152","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00262-020-02735-0","article-title":"Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.","volume":"70","author":"Qu","year":"2021","journal-title":"Cancer Immunol Immunother."},{"key":"B153","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.7150\/ijbs.70120","article-title":"CAR-T cell therapy for breast cancer: from basic research to clinical application.","volume":"18","author":"Yang","year":"2022","journal-title":"Int J Biol Sci."},{"key":"B154","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.canlet.2020.07.044","article-title":"CAR T-cell therapy for triple-negative breast cancer: where we are.","volume":"491","author":"Xie","year":"2020","journal-title":"Cancer Lett."},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0238-6","article-title":"Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice.","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis."},{"key":"B156","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11427-016-5023-8","article-title":"Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer.","volume":"59","author":"Feng","year":"2016","journal-title":"Sci China Life Sci."},{"key":"B157","doi-asserted-by":"publisher","first-page":"11054","DOI":"10.18632\/aging.102510","article-title":"EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC.","volume":"11","author":"Liu","year":"2019","journal-title":"Aging."},{"key":"B158","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10549-022-06783-1","article-title":"EGFR as a potent CAR T target in triple negative breast cancer brain metastases.","volume":"197","author":"Subham","year":"2022","journal-title":"Breast Cancer Res Treat."},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1135","article-title":"EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo.","volume":"9","author":"Xia","year":"2020","journal-title":"Clin Transl Immunol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib.","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med."},{"key":"B161","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1023\/A:1013397232011","article-title":"Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer.","volume":"71","author":"Tsutsui","year":"2002","journal-title":"Breast Cancer Res Treat."},{"key":"B162","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/path.1370","article-title":"Expression of the HER1\u20134 family of receptor tyrosine kinases in breast cancer.","volume":"200","author":"Witton","year":"2003","journal-title":"J Pathol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1121020\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:20:14Z","timestamp":1676593214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1121020\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":162,"alternative-id":["10.3389\/fmed.2023.1121020"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1121020","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,17]]},"article-number":"1121020"}}